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INTRODUCTION 
THE CHANGING PATTERN OF INFECTIVE ENDOCARDITIS 
Infective Endocarditis (IE) is a disease which 
has fascinated clinicians for many years. The clinical 
picture of the patient with IE has undergone significant 
change over the years but the basic academic and clinical 
challenge remains. In recent years, several series have 
documented the changing pattern of this disease (4,7,13, 
24,25,27,31). With the increasing life expectancy for 
the population at large, and, to an even greater extent, 
for those patients who are most vulnerable to cardiac 
infection, the average age of patients with IE and the 
number of patients in the oldest age groups have both 
increased. So too, there is now a significant likelihood 
that the patient with IE will have benefited from cardiac 
surgery, recovered from a previous episode of IE or have 
another, non-cardiac, underlying disease. 
Several authors have noted a declining proportion 
of patients with Rheumatic Heart Disease (RHD) underlying 
IE and a concomitant rise in the incidence of non-specific 
cardiac murmurs and congenital heart disease (CHD) [with 
aortic stenosis (AS) as the congenital lesion most fre¬ 
quently identified] in this population. At the same time. 

2 
the anatomical distribution of cardiac infections has 
changed. There has been a steady rise in the percentage 
of patients with isolated aortic valve (AV) involvement 
and a decline in infection involving both aortic and 
mitral valves. Similarly, the increase in narcotic 
addiction has led to an increase in tricuspid valve infec- 
tion. 
The diagnosis of IE is now made more quickly and 
the overall duration of illness has,, therefore, shortened 
significantly. As a result, the classical physical find™ 
ings of IE are seen with decreasing frequency and the 
incidence of major embolization has also declined. 
With the introduction of antibiotics, the advent 
of cardiac surgery, the increasing age of the patient 
population, and the rise in narcotic addiction, the micro- 
biological spectrum of IE has been profoundly affected 
over the past half century. The incidence of staphylococcal 
endocarditis has been rising and these infections may 
account for 20-30 percent of all cases of IE at many 
medical centers. Pneumococcal and gonococcal endocarditis, 
on the other hand, have become extremely uncommon since 
the introduction of good antimicrobial therapy. Cardiac 
infections, due to fungi and gram-negative bacilli, although 
still seen relatively infrequently, are becoming more and 
more of a problem. 
Streptococci, however, still account for more cases 
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of endocarditis than any other group of organisms. In 
most series through the late 1960's, streptococci were 
causitive in 70-80 percent of blood culture positive 
cases. More recently several authors have noted a decline 
in these figures. Pelletier and Petersdorf (31) reported 
113 cases of endocarditis with positive blood cultures of 
which 47 (42%) were caused by streptococci. Similarly, 
Cherubin and Neu (7) noted a decline in the frequency of 
streptococcal endocarditis from nearly 70 percent of cases 
recorded prior to 1957 to approximately 60 percent of all 
subsequent cases. Enterococci account for a small, but 
growing, proportion of these infections with an incidence 
of around 10 percent of all culture-positive IE noted in 
large surveys. Thus non-enterococcal streptococci still 
cause at least 30 percent and probably as much as 40-50 
percent of all IE in which an organism is isolated. If 
endocarditis in the addict and in those patients with 
prosthetic valves is not considered, these figures would 
be much higher, and, in fact, would probably have changed 
little from those reported in the 1950's and 1960's (24). 
Clearly, though, the most dramatic change in the 
clinical picture of IE occurred in the 1940's with the 
introduction of penicillin. Once a hopelessly fatal illness, 
IE became approachable from a therapeutic standpoint. Now, 
some 35 years later, after much experience with penicillin 
and a host of other antimicrobial agents, the optimal 
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treatment regimen, particularly for non-enterococcal, 
penicillin-sensitive streptococcal endocarditis, remains 
a subject of controversy. In his recent monograph on IE, 
Kaye (25) advocated a combined regimen of four weeks of 
penicillin and two weeks of streptomycin but noted the 
ongoing disagreement among infectious disease experts 
regarding the need to use combination therapy. 
The purpose of the present study centers around 
this controversy. We will attempt, first, to review the 
pertinent literature and outline the historical highlights 
that have fed this controversy. The second part of this 
investigation entails a review of the case records of all 
patients treated for non-enterococcal streptococcal 
infective endocarditis at the Yale University Hospitals 
over the past 13 years. It is hoped that within the 
limitations of a retrospective study, we shall be able to 
shed some light on the appropriate therapeutic approach 
to this important disease. 

REVIEW OF THE LITERATURE; THE TREATMENT 
OF PENICILLIN-SENSITIVE STREPTOCOCCAL 
ENDOCARDITIS 
Early in 1945, the Penicillin Trials Committee of 
the British Medical Research Council began to study the 
value of penicillin in the treatment of Subacute Bacterial 
Endocarditis (SBE). Between February of 1945 and March of 
1946, 269 patients (90 percent of which had infection due 
to viridans streptococci) were treated at 14 British 
medical centers. In these early experiments, published 
by Christie in 1948 (8), several important observations 
were made, some of which still provide the rationale for 
current treatment regimens. 
The first study demonstrated that duration of 
penicillin therapy was of greater importance than the total 
dose of such therapy. Each of 52 patients was treated with 
penicillin in a total dose of five million units 
administered over periods of five, 10, or 20 days. Eighty- 
three percent of those treated with the shortest regimen 
relapsed or died of uncontrolled infection, while 50 percent 
of those treated for 10 days and only 22 percent of those who 
were treated for 20 days, had a similarly poor outcome. 
The second phase of these early trials was designed 
5 
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to assess optimal penicillin dosage and involved 158 
patients who received treatment for 28 days with varying 
amounts of penicillin. Seventeen patients received 
100,000 units per day and seven of these patients (41%) 
relapsed or died of uncontrolled infection. Eighty-three 
additional patients were treated with a daily dose of 
250,000 units and another 58 patients received 500,000 
units per day. Thirteen of 83 or 16 percent and only four 
of 58 or 6.9 percent had recurrent infection or death with 
infection uncontrolled. 
These two studies established the importance of 
sufficient duration and dosage of penicillin therapy to 
eradicate infection in Streptococcus viridans SEE. 
Also in 1948, Spicer and Blitz (37) studied the in 
vitro response of bacterial populations to the actions of 
penicillin. These authors demonstrated that penicillin was, 
indeed, a bactericidal drug but also showed that, particu¬ 
larly with S. viridans, there were often residual organisms 
that were not killed despite varying concentrations of 
penicillin (up to 60 u/ml). These residual organisms were 
inhibited by small amounts of the same drug. They postu¬ 
lated that bacterial populations were heterogeneous and 
contained organisms capable of three different responses 
to penicillins (1) organisms that were killed by lysis; 
(2) organisms that were killed but not lysed; and, (3) 
organisms that were not killed. In addition, these authors 
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demonstrated that, despite resistance of the parent culture 
to streptomycin, the residual organisms in five of six 
strains of S. viridans could be eradicated by the addition 
of that drug. Here, then, was the first suggestion that 
antibiotic synergy might be of clinical importance in the 
treatment of S. viridans, a fact already under study for 
enterococci (20,37). 
The work of the Penicillin Trials Committee continued 
and, in October of 1949, Christie (9) published the results 
of treatment of an additional 89 new cases of culture- 
positive SEE. Seventy-one patients were treated for one 
month with 500,000 u of penicillin daily--the same regimen 
that had been reported earlier to have resulted in an 
unsuccessful outcome in less than seven percent of 58 
patients. In this new series, however, 14 of 71 patients, 
or 20 percent, relapsed or died infected. No explanation 
was apparent for these poor results. Eighteen additional 
patients subsequently received 2,000,000 u/day for at least 
one month and, at the time of publication, none of these had 
relapsed or died of uncontrolled infection. 
At about the same time. King et al. (26) attempted 
to obviate the need for prolonged therapy by markedly 
increasing the daily dosage of penicillin. In this experi¬ 
ment, eight patients with IE due to penicillin sensitive 
organisms (seven patients with S. viridans and one patient 
with a Staphylococcus) were treated with ten day courses of 
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penicillin in a daily dose of 14 million units. The 
results were dramatically poor. Bacteriological cure was 
achieved in only one of eight patients. Thus the need for 
prolonged penicillin therapy previously demonstrated by 
Christie was reaffirmed, and, in reviewing the status of 
treatment of SBE in December of 1950, Bloomfield (2) 
reemphasized the need to continue therapy for at least 
four weeks. 
Between 1950 and 1952, based in part on the pre¬ 
liminary work of Spicer and Blitz (37), Hunter (21,22) 
undertook a series of in vitro experiments designed to 
compare the action of various antibiotics and antibiotic 
combinations on streptococci. Studies were carried out 
on enterococci and viridans streptococci in systems designed 
to approximate the characteristics of the infected site in 
SBE. Hunter noted the lack of reports of spontaneous cure 
in IE and the dismal results of therapy with sulfonamides, 
aureomycin and terramycin. While these bacteristatic 
agents often were capable of suppressing the infection, cure 
with these drugs was rare. Hunter attributed the difficulty 
encountered in treating IE to the nature of the vegetation, 
which was composed of fibrin and necrotic debris, and thus 
poorly vascularized. It provided a medium in which masses 
of bacteria were free to multiply, shielded from large 
numbers of leukocyles, and host defenses. In addition, 
metabolic exchange in such a setting would take place slowly 
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and so offer a slowly growing bacterial population to 
whatever small amount of antibiotic could penetrate the 
system. 
In early studies, Hunter showed that, in cultures 
grown to maximum population density (where no further 
multiplication was possible), no antibiotic or combination 
of antibiotics, was capable of exerting a bactericidal 
effect. If an intermediate situation was achieved by 
removing half of the organisms each day (thus allowing 
limited growth at intervals), only the combination of 
penicillin and streptomycin was able to achieve a slow but 
progressive killing effect. It was postulated that this 
latter model was probably a close approximation of the 
real situation, in some vegetations, with respect to 
population density, and, that this might partly explain 
the need for intensive and prolonged therapy in SBE. It 
also gave support to the notion of combined penicillin- 
streptomycin therapy. 
In another experiment. Hunter cultured two strains 
of S. viridans in standard broth and in clotted blood, for 
the purpose of comparing the action of penicillin in varying 
doses and combined with streptomycin. It was hoped that the 
infected blood clot would parallel the situation of the 
fibrin/debris vegetation present in IE. The first strain 
was eradicated from broth in a few days by either low dose 
(2u/ml) or high dose (2Gu/ml) penicillin. Sterilization 
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took longer, i.e., seven days, with infected blood clots, 
and required the higher dose of penicillin. The addition 
of streptomycin made no difference in either situation 
with this strain of S. viridans. The second strain, how¬ 
ever, behaved quite differently, although both strains had 
minimum inhibitory concentrations (MIC's) of less than 
0.1 u/ml. Killing was again achieved in broth with either 
dose of penicillin, however, this time, sterilization 
took more than a week. In infected clots this difference 
between the two strains was still apparent but less 
pronounced, with high dose penicillin achieving steriliza¬ 
tion in twelve days. However, when streptomycin was added 
to either broth or clot infected with this second strain 
of S. viridans, the bactericidal effect was greatly 
enhanced. For example, in the infected clot, low dose 
penicillin (which used alone had no effect on either 
strain in blood clots) combined with 20 ug/ml of strepto¬ 
mycin (also totally ineffective by itself), resulted in 
complete eradication of this organism in ten days. 
Based on these experiments. Hunter suggested 
that the addition of streptomycin might be worthwhile if 
it were to allow a decrease in the duration of therapy and 
thus reduce the danger of drug toxicity. Although no 
details are given. Hunter provided clinical correlation 
with six cases of endocarditis successfully treated with 
such a short-term regimen of combination therapy. 
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Further interest in a two week treatment schedule 
for S. viridans SEE was generated in 1952 by Hamburger and 
Stein (19) who reported 12 cases treated with 15 million 
units per day of pencillin. Two patients in this series 
died--one of congestive heart failure (CHF) and one of a 
pulmonary infarction--without evidence of ongoing infection. 
Two additional patients or 16.7 percent had bacteriologicallv 
proven relapses and required retreatment with a second two 
week course. These results would appear to conflict with 
those of King discussed earlier. It may be significant 
that the patients in the earlier series were treated for 
only ten days while in those reported by Hamburger and 
Stein, treatment was continued for fourteen days. 
One year later, encouraged by the work of Hamburger 
and Stein and the preliminary data supplied by Hunter, 
Geraci and Martin (17) treated 23 patients with SBE due 
to penicillin-sensitive streptococci with a two week 
regimen of combined penicillin and streptomycin therapy. 
Five of twenty-three patients (22 percent) died. Three 
patients succumbed to CHF, one patient sustained a cerebral 
embolus and the fifth patient had a fatal myocardial 
infarction. None of the remaining eighteen relapsed or 
had persistent infection in a follow-up period that ranged 
from 3-24 months. 
In 1955, Geraci (15) reported 23 additional 
patients with similar findings. There were three deaths 
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resulting from CHF (one patient) and cerebral vascular 
accidents (two patients). Again no relapse or persistent 
infection was noted with the two week regimen of penicillin 
and streptomycin. 
In that same year, Hall, Dowling and Kellow (18) 
treated 15 patients with penicillin-sensitive streptococcal 
endocarditis with penicillin and streptomycin in combina¬ 
tion. The duration of therapy in this series ranged 
between ten and ten and seventeen days. Three patients 
were considered treatment failures, although not definite 
relapses. The first patient had persistent fever and a 
high white blood count (WBC) although blood cultures were 
sterile. He had significant mental status changes, developed 
pneumonia and died. Post-mortem examination was not 
obtained. The second patient also had persistent fever 
and died suddenly of autopsy-proven rupture of a mycotic 
aneurysm. The third patient had a relatively resistant 
organism (MIC=0.4u/ml) and remained febrile throughout 11 
days of initial therapy. Drugs v/ere stopped and the patient’s 
condition worsened. Antibiotics were reinstituted and therapy 
was continued for six weeks with a good outcome. These 
authors concluded that, based on their experience and that 
of others cited above, a ten day treatment schedule with 
two drugs would suffice in SBE caused by sensitive streptococci. 
In a review of bacterial endocarditis that appeared 
in 1956, Hunter and Patterson (23) recognized two success- 
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ful regimens for the treatment of disease due to penicillin- 
sensitive streptococci---single drug therapy with a four 
week course of penicillin in a daily dose of 2,000,000 
units or more, or combination therapy with two weeks of 
penicillin and streptomycin. The latter regimen was 
recommended by Hunter and Patterson based on the work of 
Geraci and Martin (17), Geraci (15), and Hall, Dowling and 
Kellow (18) as described above. In addition, they gathered 
146 unpublished cases treated at various medical centers 
with similar two-week---two drug schedules. Although no 
details were provided, they cited a relapse rate of six 
percent and concluded that these two protocols for treating 
non-enterococcal streptococcal endocarditis were comparable. 
Shortly after this review appeared, Tompsett and 
his co-workers (41) reported more disappointing results in 
treating 35 endocarditis patients who had infections caused 
by streptococci inhibited by less than 0.4 u/ml of penicillin. 
All were treated with short-term combination therapy con¬ 
sisting of 6,000,000 units of penicillin and two grams of 
dihydrostreptomycin daily. Four cases (11.1%) had bacterio- 
logically proven relapses (MIC's for the organisms isolated 
from these patients were less than 0.1 u/ml) and four addi¬ 
tional patients had persistent fever or other clinical 
signs of possible continued infection which necessitated 
continued antibiotic therapy despite sterile blood cultures. 
These results suggested that a two week regimen was inadequate 
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for some patients. Because of the impossibility of pre- 
dieting which patients might require prolonged therapy,, 
these authors suggested the routine extension of treatment 
to 21-28 days. 
Later in 1958, however, Geraci (16) reviewed the 
Mayo Clinic experience. In this large series, a proportion 
of which had been ■'reported earlier (15,17), only three 
relapses (one definite, two probable) occurred, giving a 
bacteriological failure rate of four percent. The drug 
dosages employed at the Mayo Clinic--2,000,000 units of 
penicillin and one gram of streptomycin daily--were lower 
than those used by Tompsett et al. 
No major developments occurred over the next several 
years and in 1964 the subject was again reviewed by 
Tompsett (39). He concluded that, while it seemed unlikely 
that even a four week regimen would be 100 percent effective, 
it would be unsatisfactory to accept bacteriological cure in 
92-95 percent of patients without first establishing that 
these were the upper limits of any regimen. His recommenda¬ 
tions, therefore, were to administer combination therapy 
with 4,000,000 units of penicillin and one gram of strepto¬ 
mycin daily for two weeks and to then continue penicillin 
alone for an additional two weeks. There were no relapses 
in 24 patients treated with this regimen although no specific 
details of these patients were provided. 
In 1971, Tan et al. (38) described their experience 
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with 49 patients with S. viridans SBE. Thirteen patients 
received two week courses of 15-20 million units per day 
of penicillin and no other drug. Two of thirteen (15%) 
relapsed. Thirty-six patients were treated for two weeks 
with either penicillin-G (parenterally) or penicillin-V 
(orally) in combination with streptomycin. There were no 
relapses in this group and these authors concluded that 
two week combination therapy was adequate treatment in this 
disease. 
Further support for prolonged (four week) therapy, 
combined with an aminoglycoside for the first two weeks, 
came in 1973 when Kaye (24) reported a series of 70 patients 
treated at the New York Hospital with four weeks of procaine 
penicillin (4,800,000 units/day) and two weeks of streptomycin 
(l.Og/d) without a single relapse. All organisms were 
inhibited by less than or equal to 0.16 u/ml of penicillin 
but no other details of these 70 cases were provided. 
In 1974, Sande and Irvin (34) and Durack, Pelletier 
and Petersdorf (10) demonstrated that the combination of 
penicillin and streptomycin was more efficient in eradicating 
experimentally induced S. viridans endocarditis in the 
rabbit than either drug alone. The experiments carried out 
by Sande and Irvin revealed that bacteremia and fever per¬ 
sisted longer in rabbits treated with penicillin alone as 
compared with animals receiving a combination of the drugs. 
Furthermore, these authors observed that experimentally 
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induced vegetations could be sterilized in 3-4 days using 
a combination of penicillin and streptomycin while 7-10 
days were required when only penicillin was employed. 
Similarly, Durack, Pelletier and Petersdorf were not able 
to sterilize vegetations in this same rabbit model by using 
i 
either penicillin or streptomycin alone, for one to three 
days, but could completely eradicate the streptococci in 
eight of eight rabbits receiving both drugs for 12 hours. 
Also in 1974, Wolfe and Johnson (46) observed the 
activity of penicillin, streptomycin and a combination of 
both agents in 48 strains of penicillin-sensitive streptococci 
(MIC's for penicillin £0.4 ug/ml). None was killed by 
streptomycin (10 ug/ml) alone and only one of 48 was killed 
by penicillin (1.6 ug/ml). Thirty-seven of the 48 strains, 
however, were eradicated by the combination of 0.8 ug/ml of 
penicillin with 5.0 ug/ml of streptomycin. In this same 
report, Wolfe and Johnson recounted their experience with 
thirty-five patients treated with two weeks of penicillin 
plus streptomycin followed by two weeks of penicillin alone. 
No relapses occurred. 
Recently, Pelletier and Petersdorf (31) reviewed the 
University of Washington Hospital's experience with IE 
between 1963 and 1972. There were 28 patients with non- 
enterococcal streptococcal endocarditis and nineteen of the 
twenty-eight received single drug therapy whereas nine 
patients received combination therapy. There was no 
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significant difference in relapse rate between these two 
groups of patients (4/19=21% vs. 1/9=11%). This relapse 
rate, however, (5/28=18%), is higher than those previously 
reported. One patient in this study relapsed after two 
weeks of penicillin and streptomycin in combination. A 
second patient received seventeen days of penicillin and 
seven days of streptomycin and then died suddenly of 
ventricular fibrillation complicating an acute inferior 
wall myocardial infarction. Viable S. viridans were present 
in vegetations on the AV and the Sinus of Valsalva. Patient 
number three was treated for two months with 30 million 
units of penicillin per day plus probenicid, combined with 
chloramphenicol for three weeks. In this case, the combina¬ 
tion of a bacteriostatic drug with penicillin may have 
resulted in inhibition of bactericidal activity. The 
fourth patient received penicillin for one month, under¬ 
went valve replacement (for CHF) and, one month after 
operation, had recurrent disease. Post-operative reinfection 
with a similar organism remained a possibility in this case. 
No information is available about the fifth probable relapse. 
Finally, Phair and Tan (32) reported 85 patients 
treated for S. viridans endocarditis. Thirteen of 85 
received penicillin alone for 11-17 days, eight patients 
received penicillin alone for more than 21 days, 39 patients 
received penicillin and streptomycin in combination for 
11-17 days and 25 patients received penicillin for 21 days 
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or more plus streptomycin for at least twelve days. There 
were six relapses in this series (6/85=7%). Three of 
twenty-one patients treated with penicillin alone relapsed 
(14%) compared with three of 64 patients who had received 
combination therapy (5%) . Phair and Tan also noted a 
relationship between relapse and duration of illness. Five 
cases of recurrent endocarditis occurred in 25 patients 
who had had symptoms for longer than three months while 
only one of 60 patients with IE of shorter duration suffered 
a relapse. These authors suggested that a 14 day course of 
therapy with penicillin and streptomycin in combination 
is appropriate for patients with penicillin-sensitive 
streptococcal endocarditis who have been ill for less than 
three months but that penicillin should be continued for 
an additional two to four weeks when disease has been 
present for a longer period of time. 
Several important aspects of the treatment of IE 
due to non-enterococcal penicillin-sensitive streptococci 
are clearly illustrated in reviewing the literature; 
1) Treatment with a single agent for less than three 
weeks may be associated with relapse rates of 17% 
or greater (19,26). 
2) Cure in better than 90% of patients will be achieved 
with any of the following regimens; 
a) Four weeks of Penicillin at 2,000,000 units per 
day or more. 
No data is available on four week treatment 
with penicillin alone in doses conventionally 
employed today (5-6,000,000 units or more daily). 
Christie's early work (8,9), and subsequent reviews 
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of the subject of SBE (3,12,23,25,39) indicate 
that cure can be achieved in approximately 95% 
of cases. 
b) Two week treatment with penicillin and 
streptomycin. 
A large number of patients treated with this 
regimen are discussed in the literature with 
relapse rates ranging from 0 to 11% although the 
largest series observed a relapse rate of 4-6% 
(15,16,17,18,38,39,40,41). 
c) Four weeks of penicillin combined with two 
weeks of streptomycin. 
/although several authors have suggested that 
this treatment regimen is 100% effective, the 
results of their work are not detailed (24,25,39, 
40,46). Moreover, instances of treatment failure 
with this regimen have been reported (32). 
Since it is possible that the cure rate with 
this latter regimen may approach 100%, any other regimen 
must offer similarly good results and/or significantly less 
danger of drug toxicity to be considered as the treatment 
of non-enterococcal, penicillin-sensitive streptococcal 
endocarditis. Penicillin alone (regimen a above) may, in 
fact, achieve these goals. It is unfortunate that so little 
data is available on this four week treatment regimen. 
Since the study of IE has been in progress for more 
than a decade at the Yale University Medical Center, it 
seemed reasonable that a sufficient number of cases would 
be available to serve as a basis for comparison of regimens 
involving three weeks or more of therapy with and without 
an aminoglycoside in the treatment of IE due to penicillin- 
sensitive streptococci. 

METHODS 
I. PATIENT POPULATION 
At the two Yale University hospitals--the Yale- 
New Haven Hospital (YNHH) and the West Haven Veterans 
Administration Hospital (WIIVAH) all available records 
bearing a discharge diagnosis of Bacterial Endocarditis 
between July 1, 1964 and June 30, 1917, were examined. 
Of 176 charts so coded at the YNHH during this interval, 
121 records were available for review. At the WHVAH, 
where this discharge diagnosis appeared 41 times, there 
were 35 records that could be examined. 
Of these 156 available records, only patients 
with non-enterococcal, streptococcal infective endocarditis 
(IE), who met the following criteria, were included in 
the present studys 
1) Two or more blood cultures positive for a single 
non-enterococcal, streptococcal organism. 
2) A clinical history compatible with IE. 
3) A heart murmur. 
Encocarditis caused by any other organism, as well 
as all culture-negative cases, and all cases of marantic 
endocarditis were excluded from consideration. 
Of the 156 records available for review, 69 cases 
20 
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[in 68 patients], fulfilled these criteria and form the 
basis of the present study. [The remaining 88 case records 
included 49 cases caused by other organisms, 16 miscoded 
charts, 16 culture-negative episodes, three cases of marantic 
endocarditis and four cases of possible streptococcal 
endocarditis whose clinical history and/or course of ill¬ 
ness were not consistent with the diagnosis.] 
II. DATA COLLECTION 
Data on these 69 cases were collected by means of 
a careful review of the hospital record. The entire group 
was characterized as to sex, age, underlying cardiac condi¬ 
tions, pertinent past medical history, presenting symptoms 
and the duration of illness, physical findings and laboratory 
abnormalities. The identity of the causative organism and 
its antibiotic sensitivity was noted. Data was analyzed to 
assess the prognostic importance of these various factors 
for this population. 
The parameters which we considered most significant 
in evaluating prognosis and outcome in this disease were : 
1) the development of CHF 
2) requirement of valve replacement 
3) occurrence of major embolic phenomena 
4) persistence of fever without other evidence of 
ongoing infection 
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5) recurrent disease, and 
6) death. 
Persistent fever was considered significant when 
it was judged unrelated to hypersensitivity and necessi- 
tated. a change in therapy. In all cases blood cultures 
and operative specimens were sterile. 
Recurrent disease was defined as any case requiring 
retreatment for endocarditis with an identical organism 
occurring within six months of completion of initial therapy. 
III. ASSESSMENT OF THERAPY 
Patients were divided into two groups. Group I 
patients received penicillin, a cephalosporin, lincomycin 
or vancomycin and three days on less of an aminoglycoside. 
Group II patients were treated with either penicillin or a 
cephalosporin in combination with 5-28 days of aminoglycoside 
therapy. 
Data was analyzed to detect any basic differences in 
the two groups with regard to both parameters demonstrated 
as having prognostic significance in our population, as well 
as those factors reported by other investigators to influence 
outcome in IE. 
Finally outcome for patients in both groups was 
studied to determine whether the addition of an aminoglycoside 
for more than three days improved the prognosis in non- 
enterococcal streptococcal IE. 
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IV. DATA ANALYSIS 
Frequencies and means as presented in Results are 
based on all patients for whom such data was available. 
The divisor, i.e., the number of patients on whom the 
particular observation was made, is given in all cases. 
2 
Data was analyzed using the t-test and X -test. 
Where appropriate the Yates correction for the latter test 
was applied (1,6). 

RESULTS 
A] SEX 
Of the 69 patients reported here, 46 were male 
and 23 were female, so that the male:female ratio was 2:1 
(Table 1). A male predominance still existed after correct¬ 
ing the ratio for eight male patients provided by the WHVAH. 
Thus a corrected sex ratio of 38:23 or 1.7:1 occurred. The 
higher incidence of IE in males has been previously noted 
(27,31,36). 
Table 1 also shows the distribution of males and 
females by anatomical site of endocarditis. Twenty-one of 
26 cases (81%) with aortic valve involvement and 6 of 7 
cases (86%) of prosthetic valve endocarditis occurred in 
males, while 16 of 27 patients (59%) with mitral valve 
infection and only 3 of 9 patients (33%) with non-valvular 
congenital lesions were male. Male predominance, particu¬ 
larly in AV endocarditis, has also been observed before (31). 
B] AGE 
The average age for all patients included in the 
present study was 44.4 years and ranged between 8 months 
and 80 years (Table 2). This figure is similar to those 
reported by Pelletier and Petersdorf (31) and Cherubin and 
Neu (7) and supports recent observations by these authors 
24 
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TABLE 1 
RATIO OF MALES TO FEMALES IN 69 PATIENTS 
WITH NONENTEROCOCCAL STREPTOCOCCAL 
ENDOCARDITIS 
Sitea 
YNHH 
Male 
and WHVAH 
Female Ratio Male 
YNHH ONLY 
Female Ratio 
AV 21 5 4.2:1 17 5 
i—i
 
ro
 
MV 16 11 1.5:1 14 11 1.3:1 
CONG 3 6 
i
—i
 
LO
 
o
 
3 6 
i—i
 
LO
 
c
 
PROSTH 6 1 
i
—i
 
o
 
4 1 
1—1
 
o
 
All 4 6 23 
i—1
 
oq
 38 23 1.7:1 
a) AV= :Aortic Valve MV=mitral valve 
CONG=Non-' valvular congenital lesion 
PROSTH=Prosthetic valve 
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of the increasing age of patients with IE. There was no 
significant age difference between males and females. 
Patients with infection of a prosthesis or of the mitral 
valve were slightly older, although this difference was 
not significant. The mean age of 16.4 years for patients 
with non-valvular congenital lesions was significantly 
lower than that for any other group of patients (p <0.001) 
C] UNDERLYING HEART DISEASE 
There was evidence of some cardiac abnormality 
prior to presentation with IE in 83 percent of cases 
reviewed (Table 3). Twenty-four patients (35%) had congeni 
tal heart disease (CI-ID) . Fifteen of these 24 had definite 
involvement of the aortic or mitral valve [10 AV patients 
including one with IHSS, 3 patients with congenital MR, 
and 2 patients with MR secondary to MV Prolapse Syndrome]. 
In two of these fifteen patients--one with AR and one with 
MR—-there was a coexisting VSD. [For all other considera¬ 
tions, data for these fifteen patients have been analyzed 
with data for other patients with infection of the same 
heart valve.] Of the remaining nine patients with CHD, 
three had Fallot's tetralogy, two had VSD's, and one had 
a patent ductus arteriosus (PDA). The diagnosis was not 
specified in three patients. 
Twenty-one of 69 patients (30%) had a heart 
murmur documented on at least two occasions prior to 
hospitalization for endocarditis but no specific diagnosis 
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had been applied to these patients. In 16 of 21 the 
murmur was simply described as systolic, while in five 
patients the murmur had been characterized as to valvular 
site (AV vs. MV) and type of pathology (regurgitation vs. 
stenosis). It is probable that three patients in this 
latter group--(one patient with MR; one with MR,MS,AR; one 
with MR,AR,AS)--and, perhaps several members of the former 
group, had rheumatic heart disease (RED). 
Seven patients (10%) are considered to have had 
valvular prostheses underlying their infection. Six of 
these seven are men who had actually undergone valve replace¬ 
ment. Two of these had known RED and four carried no 
etiologic diagnosis. The seventh patient is a woman who had 
an aortic valvuloplasty with residual suture material in 
her reconstructed valve. 
Five additional patients (7%) actually carried the 
diagnosis of RED. Although several authors (7,31) 
have recently pointed out the decreasing prevalence of RED 
as an underlying problem in patients with IE, the percentage 
of patients who actually carried this diagnosis would seem 
to be much smaller in our series. Possibly, part of this 
discrepancy is due to a failure to apply an etiologic label 
to patients with cardiac murmurs who had true RED but no 
clear-cut history of rheumatic fever. 
In 12 of 69 patients (17%) no underlying cardiac 
abnormality had been previously recognized. 
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D] NON-CARDIAC UNDERLYING DISORDERS 
Other factors which might have a significant impact 
on the course of IE are tabulated in Table 4 according to 
the frequency with which they occurred in our population. 
In seven cases there was a prior history of congestive 
heart failure (CHF) and in seven cases there had been a. 
previous episode of IE. Coronary artery disease (CAD) 
was a factor in 6 patients, three of which had had a docu¬ 
mented myocardial infarction in the past. Small numbers 
of patients had cancer, diabetes mellitus, renal failure 
or liver impairment secondary to excessive alcohol ingestion. 
E] PRESENTING SYMPTOMS 
Presenting symptoms for all patients are listed in 
Table 5. Fever occurred in 84 percent of patients. Non¬ 
specific complaints of fatigue, weakness and malaise were 
the next most common symptoms, occurring in 39 of 69 patients 
(57%). Ten patients or 15 percent of our group complained 
of new or increased symptoms of congestive heart failure. 
Neurological complaints including stroke, confusion, stupor 
and obtundation were obvious in eight patients (12%). One 
patient presented with both flank pain and hematuria. These 
figures parallel those reported in other large surveys 
(7,31,36). 
F] DURATION OF SYMPTOMS 
For 64 cases where data was available, the mean 
length of time between the onset of the first symptom related 
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TABLE 5 
PRESENTING SYMPTOMS IN 69 PATIENTS WITH NON-ENTEROCOCCAL 
STREPTOCOCCAL ENDOCARDITIS 
Symptom Number o. 'o 
Fever 57 (84) 
Fatigue, weakness, malaise 39 (57) 
Chills 24 (41) 
Anorexia, weight loss 20 (29) 
Sweats 13 (19) 
A.rthralgias 12 (18) 
Myalgias 10 (15) 
CHFa 10 (15) 
Headache 8 (12) 
Stroke, confusion, stupor 8 (12) 
Cough 7 (10) 
Abdominal pain, nausea, diarrhea 6 ( 9) 
Chest pain 5 ( 7) 
Back pain 3 ( 4) 
Flank pain 1 ( 1) 
Hematuria 1 ( 1) 
a) New or suddenly increased congestive heart failure. 
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to IE and presentation to the hospital was 51.2 days 
(Table 6). This is slightly lower than has been docu¬ 
mented elsewhere (31). Patients with prosthetic valve 
infection had much shorter duration of symptoms (mean 
12.6 days) prior to hospital admission (p <0.01). 
G] PHYSICAL FINDINGS 
The classical signs of infective endocarditis were 
not commonly seen in the patients in the present study. 
Table 7 summarizes the physical findings noted within the 
first few days of hospitalization. All patients had a 
cardiac murmur and 66 of 69 patients had fever greater than 
100.6°F. Splenomegaly was seen in 14 patients (20.3%), 
whi1e petechiae and splinter hemorrhages occurred in 17.4% 
and 14.5% of cases respectively. Clubbing was noted in 
only four patients (5.8%) as a new finding and Roth spots 
were described in three patients. Two patients had at least 
one Janeway1s lesion each. No Osier's nodes were described. 
H] LABORATORY STUDIES 
(Table 8) An elevated erythrocyte sedimentation 
rate (ESR) was the most constant laboratory finding and 
occurred in 49 of 54 patients (90.7%) with a mean value of 
40.9. Fifty-three of 63 patients or 84.1% of our group 
were anemic; the mean hematocrit was 33.1%. Reversal of 
the albumin: globulin ratio occurred 21 of 43 patients (48.8%) 
in whom measurement of serum proteins was performed. The 
mean white blood count (WBC) was 9400 with 28 of 67 patients 
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TABLE 6 
DURATION OF ILLNESS PRIOR TO TREATMENTa IN 64b PATIENTS 
WITH NON-ENTEROCOCCAL STREPTOCOCCAL ENDOCARDITIS 
Site0 Number of Patients 
Median 
Duration 
(Mean + SE) (Days) 
AV 24 42 52.5 + 11.8 
MV 25 30 58.9 + 12.2 
CONG 9 14 53.2 _L 35.5 
PROSTH 6 7 12.6 + 6.2 
All Patients 64 30 51.2 + 8.4 
a) Period beginning with first symptom attributed to IE. 
b) Data unavailable for 5 patients. 
c) AV = aortic valve MV = mitral valve 
CONG = non-valvular congenital lesion 
PROSTH = prosthetic valve 
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TABLE 7 
PHYSICAL FINDINGS ON PRESENTATION IN 69 PATIENTS WITH 
NON-ENTEROCOCCAL STREPTOCOCCAL ENDOCARDITIS 
Sign Number (%) 
Murmur 69 (100) 
Fever 66 (96) 
Splenomegaly 14 (20) 
Petechiae 12 (17) 
Splinter Hemorrhages 10 (15) 
Clubbing 4 (6) 
Roth Spots 3 (4) 
Janeway's Lesions 2 (3) 
0 (0) Osier's Nodes 
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having a WBC in excess of 10,000. Rheumatoid Factor was 
present in titers of at least Is 40 in 32.7% of patients 
(16/49). Hematuria and proteinuria were detected less 
frequently (15/68 or 22.2% and 9/68 or 13.2% respectively). 
I] FOLLOW-UP 
Six patients died within or just after the treat¬ 
ment period. Of the remaining 63 patients, all were 
followed for at least six months with a mean duration of 
follow-up of 53.9 months. Thirty-eight of 63 were followed 
for more than one year. 
J] INFECTING ORGANISMS 
The streptococci isolated from blood cultures in 
these 69 patients are listed in Table 9. Minimum Inhibitory 
Concentrations (MIC's) for penicillin were done on approxi¬ 
mately half of the organisms isolated and were less than 
0.19 u/ml in all cases. 
K] MORBIDITY 
Table 10 describes major complications (including 
death) of endocarditis seen in these 69 patients during the 
period beginning with the onset of disease-related symptoms 
and ending six months after completion of therapy. Thirty- 
three of 69 patients (49.3%) developed one or more major 
complication; 36 patients (50.7%) had an uneventful course. 
Twenty-three patients (33%) developed CHF or had a sudden 
worsening of a previously stable pattern of CHF. Fifteen 
of 23 patients had AV endocarditis, three patients each had 
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prostheses or mitral valve disease and two had non- 
valvular CHD. Thus, 58 percent (15/26) of patients with 
IE involving the AV and 43 percent (3/7) of those with 
prostheses developed CHF compared with 11 percent of MV 
patients (3/27) and 22 percent of those with non-valvular 
CHD (2/9). The AV and prosthetic valve predominances in 
the development of CHF were highly significant (p <0.001) 
and are consistent with the findings of other investigators 
(33,35). Eight patients had definite, major embolic 
episodes including stroke (6 patients) and major peripheral 
arterial occlusion (ophthalmic a.-l, femoral artery -1). 
Three patients had persistent fever, felt to be unrelated to 
hypersensitivity, despite repeatedly sterile blood cultures. 
All three patients came to operation. In one a mycotic 
aneurysm near the aortic valve ring was identified, while 
in the other two patients there was no obvious source of 
fever. Fever abated following valve replacement in these 
three patients, although operative specimens in all cases 
were sterile on culture, including culture for L-phase 
variants. There were two recurrences in our group, both 
occurring within one month of completion of a course of 
therapy (3%). Six of the 69 patients died (a mortality 
rate of 8.7%). 
Of the 33 patients developing major complications, 
26 developed a single complication, five developed two 
complications and two patients suffered three complications. 
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Two patients with persistent fever had another complication 
of IE--one developed CHF and one sustained a sterile 
femoral artery embolus after undergoing valve replacement. 
The other five patients with multiple complications; all 
died. One presented with CHF, relapsed and died suddenly 
shortly after readmission. Two additional patients had 
developed CHF, and subsequently died, another presented 
with a stroke and died and, finally, one presented with a 
stroke and CHF succumbing only two days after admission. 
What is clearly evident from Table 10 is that 
patients with prosthetic valve endocarditis did extremely 
poorly. Two patients died (29%) and four patients required 
re-replacement of their valve. The course in two of these 
six was further complicated by major emboli resulting in 
a stroke in one patient and occlusion of a femoral artery 
in the other. Only one patient had an uneventful course. 
Thus six of seven patients (86%) developed seven major 
complications of IE. This complication rate was signifi¬ 
cantly higher than that in the remainder of patients (86% 
vs. 45%, p <0.05). 
L] INFLUENCE OF UNDERLYING FACTORS, AGE AND MODE OF 
PRESENTATION ON OUTCOME IN IE 
Table 11 describes major complications of endocarditis 
as they occurred in individuals with various underlying 
conditions which have been implicated in worsening the 
prognosis in this disease (30). Patients with prosthetic 
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valve endocarditis were not included in this analysis 
because of their already grave prognosis as discussed 
above. Although the numbers are small, there does not 
appear to be any definite relationship between these 
factors (H/0 CHF, H/0 SEE, CAD, Cancer, D„M„, Renal Fail¬ 
ure, EtOH Excess) and outcome for this group of patients. 
Similarly, the data was analyzed to determine 
whether, as in several other series (5,8,31), there was a 
relationship between presentation with CHF or symptoms 
referable to the central nervous system (CNS) and outcome 
in IE. Eight patients presented with CHF. Five of eight 
had AV endocarditis, one had MV endocarditis and two had 
endocarditis associated with non-valvular congenital 
lesions. Four of eight (all AV patients) required place¬ 
ment of a prosthetic valve. In three of these, CHF was 
the sole indication for surgery while in the fourth patient 
the primary factor leading to operation was persistent fever. 
One patient in this group--who also presented with a CVA-- 
died within 48 hours of admission. The incidence of compli¬ 
cations (valve replacement, fever, death) was not signifi¬ 
cantly greater in this group than for all patients or for 
patients who developed CHF later in the course of illness 
(p >0.20, p >0.20). 
Eight patients presented with either a stroke or 
significant neurological impairment (stupor, obtundation) 
felt to be related to IE. Six of these patients had 
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no complications. Two of the eight patients (25%), how¬ 
ever, died. This death rate was not significantly greater 
than that for all other non-prosthetic patients (p > 0.10). 
Patients at the extremes of age have reportedly 
faired poorly in IE (5,8,30,31). Only four patients 
reported here were less than ten years old and none of 
these developed a major complication. On the other hand, 
twenty patients were in the seventh decade of life and 
these patients accounted for all four deaths (20%) and 
both episodes of recurrent disease (10%) in non-prosthetic 
IE. Both the relapse rate and the mortality rate were 
significantly greater than for patients under 60 years old 
(p <0.05, p <0.01 respectively). 
Patients who were to develop a major complication 
of IE had a significantly longer symptomatic period prior 
to presentation than those x*7ho had an uncomplicated course 
(69 vs. 35 days, p <0.01). 
Analyzing the data from 58 non-prosthetic endo¬ 
carditis patients (as was noted in section F, PV patients 
had a much shorter duration of illness), it can be shown that 
patients who developed CHF were, on the average, symptomatic 
for 79 days prior to hospitalization and, furthermore, 
that those who ultimately required valve replacement because 
of CHF, presented after a mean of 99 days of symptoms 
(Table 12). Both of these values contrasted sharply with 
the duration of illness in non-prosthetic endocarditis 
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patients who had no complications (mean 35 days; p < 0.001, 
p <0.001). The relationship between duration of illness 
and development of CHF has been previously observed 
(3,8,30). 
The mean duration of illness in patients who developed 
major emboli (56 days) and those who died (63 days) was 
also longer than in those patients who had no complications 
although these differences were not significant (p >0.05). 
Patients who developed persistent fever had a very short 
pre-treatment duration (18 days), but again this was not 
significantly different from the mean duration of illness 
in patients with uncomplicated IE (p >0.05). Both of the 
patients who relapsed had four month histories prior to 
hospital admission. This was significantly longer than 
the duration of illness in patients who had uneventful 
courses (p <0.001). 
In addition, patients with illness prior to therapy 
of three months or greater had a higher incidence of relapse 
than those with illness less than three months prior to 
therapy (Table 11). The relapse rate for patients with 
longstanding illness was 15.4 percent (2/13) and was 
significantly higher than the rate for the remainder of 
patients on whom data was available (0/51, p < 0.05). This 
observation has been made by others (32). It was also 
noted that patients with illness greater than or equal to 
three months in duration developed CHF with greater 
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frequency than all other patients, but this difference was 
not significant (7/13 or 54% versus 13/51 or 26%, p >0.05). 
M] TREATMENT 
Of the 69 patients discussed above, 68 patients 
survived for at least one week and are included in the 
analysis of efficacy of antimicrobial therapy. One patient 
died within 48 hours of admission so that therapy could 
not be evaluated. 
GROUP I: Forty-nine of 68 patients were treated 
with a bactericidal antibiotic and three days or less of 
an aminoglycoside. Of these, 41 patients received penicillin 
and eight patients received a cephalosporin, lincomycin 
or vancomycin singly or in sequence. Eleven of these 49 
patients received an aminoglycoside for three days, five 
additional patients received two days of aminoglycoside therapy 
and three other patients received streptomycin for one day. 
The remaining thirty patients received single drug therapy. 
Figure 1 illustrates the duration of antibiotic 
therapy for all Group I patients which ranged from 7-50 
days with a mean of 30.2 days. Eleven patients (22%) were 
treated for 21 days or less. Two of these died within the 
first two weeks of therapy; the remaining nine received 
15-21 days of antibiotic. Sixteen patients (33%) were 
treated for a period of 22-28 days and 22 patients (45%) 
received more than 28 days of therapy. 
Parenteral penicillin was given intravenously for 
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FIGURE l. DURATION OF THERAPY IN 49 GROUP I PATIENTS. 
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at least one week in 39 of 41 penicillin treated patients. 
Dosage ranged from 2,000,000 units per day in a three 
kilogram infant, to 24 million units per day. One adult 
patient received 4,000,000 units daily and four patients 
were treated with 8,000,000-9,000,000 units per day. The 
remaining 33 patients received 10 million units or more 
each day. Six of these 39 patients received the latter 
part of their therapy intramuscularly in dosages of 2.4- 
4.8 million units daily and ten patients received some 
oral penicillin in dosages that ranged between 2™4 grams 
daily. 
Intramuscular penicillin was the primary form of 
therapy in the remaining two of 41 patients. One patient 
received 4.8 million units per day for 21 days while the 
other patient began his 28 day course with two days of 
intravenous penicillin (24 million units/day) and continued 
with intramuscular penicillin in doses of 4.8 million units 
per day for one week, 3.6 million units per day for one 
week and 2.4 million units per day for the last twelve days. 
The remaining eight of 49 Group I patients received 
the following agents, employed singly or sequentially, during 
the course of treatment: cephalothin (6-9g/d, IV or I.M), 
cephaloridine (4g/d, IM), lincomycin (l-6g/d, IM), 
vancomycin (2g/d, IV) and chloramphenicol (4g/d, I.M). 
Details of treatment for each patient in Group I may 
be found in Table 13. 
GROUP II: The 19 remaining patients (49 + 19_ = 6 8) 
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formed the second treatment group where each patient had 
received parenteral penicillin (17 cases) or a cephalos¬ 
porin (2 cases) in addition to at least five days of an 
aminoglycoside. 
The mean duration of therapy for Group II patients 
was 27.0 days (range: 14-42 days) (Figure 2). Six Group II 
patients (32%) were treated for 21 days or less. One of 
six died after two weeks of therapy; the other five patients 
received 21 days of antibiotics. Eight patients (42%) 
received antibiotics for 22-28 days and the remainder 
received longer courses. 
The pattern of administration of the aminoglycoside 
is illustrated in Figure 3. Duration of aminoglycoside 
therapy ranged from 5 to 28 days with a mean of 13.3 days. 
Three patients received an aminoglycoside for less than a 
week, five additional patients were treated with an 
aminoglycoside for 7=10 days, six patients received an 
aminoglycoside for 11-14 days and the remaining 5 patients 
received at least three weeks of such therapy. Six patients 
received gentamicin; 13 patients received streptomycin. 
Penicillin was the only drug given in addition to 
the aminoglycoside in 17 of 19 patients and in all but one 
of these patients, it was administered intravenously in 
doses of at least 10 million units daily. The seventeenth 
patient received 4.8 million units per day intramuscularly 
for 18 days and then intravenous penicillin (10 million units/ 

BS 
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day) for an additional nine days. 
Two of 19 patients received a cephalosporin. One 
patient received cephazolin in a dose of 2.0 grams per day 
intravenously for 21 days. The other patient was begun on 
penicillin for two weeks and,, when a question of drug allergy 
arose, was changed to cephalothin, 8.0 grams per day, for an 
additional 20 days. 
Details of treatment for Group II patients are 
outlined in Table 14. 
N] MONITORING THERAPY 
Efficacy of antibiotic therapy was assessed with 
serum bactericidal levels in 48 of these 68 patients. Thirty- 
four of 49 (69%) had titers of 1:16 or greater, 11 had a 
titer of 1:8 while only three patients had titers of less 
than 1:8. None of the three patients in the latter group 
suffered any major complication of endocarditis. 
The erythrocyte sedimentation rate (ESR) and rheumatoid 
factor (RF) were repeated in so few patients that no state¬ 
ment can be made about these parameters as monitors of 
therapy. 
O] COMPLICATIONS OF THERAPY 
A rash occurred in five Group I patients treated 
with penicillin and resulted in a change in medication to 
cephalothin in all cases. Four of these five patients, 
however, showed continued signs of hypersensitivity to the 
second drug, requiring a further alteration in therapy. 
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One additional patient in Group I developed hives while on 
penicillin and, again, on cephalothin. Superficial 
phlebitis at the site of penicillin infusion posed some 
difficulty for a patient in Group II. 
A history of penicillin allergy was obtained from 
four patients (Group 1-3; Group II-l). Three of these 
received alternative agents while the fourth patient was 
desensitized to penicillin and underwent uncomplicated 
treatment with that drug. 
A transient ataxic tremor developed in one Group II 
patient and resulted in discontinuation of streptomycin 
therapy. 
P] COMPARISON OF GROUPS; I-SINGLE DRUG II-COMBINATION 
THERAPY 
The data was analyzed to detect any underlying 
differences between the two treatment groups which might 
have had an effect on the course of the disease (Table 15). 
The mean age of Group I patients was higher than that of 
Group II patients but this difference was not significant 
(49.9 years vs. 40.9 years, p > 0.05). The percentage of 
patients in their seventh decade of life, however, was 
significantly higher than in Group II, i.e., 18 of 49 or 
36.7% of Group I patients were over 60 years old as opposed 
to only two of 19 Group II patients (10.5%) (p < 0.05). 
Moreover, the proportion of patients in Group I having IE for 
a period of three months or more prior to treatment was 22.4% 
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(11/49) and was significantly larger than the percentage 
with a greater than three month pre-treatment duration in 
Group II (2/19=11%, p <0.05) even though the mean duration 
of illness in Groups I and II (52.6 vs. 55.2 days) did not 
differ significantly. No significant differences between the 
two groups were noted when other factors were analyzed. The 
distribution of anatomical sites of involvement was roughly 
equivalent and, while there were slight differences in the 
percentages of patients having various underlying conditions 
or presenting with CHF or CNS symptomatology, none of these 
was significant. Similarly, the duration of therapy did 
not differ between Groups I and II with means of 30.2 and 
26.9, respectively. 
Q] COMPARISON OF OUTCOME: GROUP I vs. GROUP II 
The incidence of major complications of IE, occurring 
in each of the two treatment groups, during the period beginning 
one week after initiation of therapy and ending six months 
after therapy, is summarized in Table 16. For the purposes 
of these analyses, complications whose onset antedated the 
initiation of a therapeutic regimen, were not considered. 
Of 68 patients assigned to either treatment group, 
49 were in Group I and 19 in Group II. Thirty-eight and 
eight tenths percent of patients in Group I (19 of 49) 
developed one or more major complication. The comparable 
figure for Group II was 26.3% (5/19). This difference, 
however, was not significant (p > 0.30). 
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A total of thirteen patients (13/68=19%) developed 
CHF during this period. Ten of thirteen were Group I 
patients and six of these ten required valve replacement 
(AVR-4; MVR-1; Prosth Re-replacement-1). Three patients 
in Group II developed CHF, two of them requiring operation 
(AVR-1, Prosthesis Re-replacement-1). The differences in 
the incidence of CHF--10/49 (20%) in Group 1 versus 3/19 
(16%) in Group Il — and in the rate of valve replacement 
were not significant (p >0.50, p > 0.50) . 
Although major emboli occurred in four patients, 
all of whom had received single drug therapy (Group I) as 
compared to none in Group II, this difference was not 
significant (p >0.50). Persistent fever occurred in 
three patients--one from Group I (2%) and two from Group 
II (11%) and this was not significantly different (p > 0.50). 
CASE 36-PERSISTENT FEVER: This patient 
was a ten year old white male who presented 
with a three week history of anorexia, a mild 
cough, and several days of flank pain and 
hematuria. Physical examination revealed 
palatine petechiae and splenomegaly in addi¬ 
tion to a harsh grade IV/VI systolic ejection 
murmur. The hematocrit was 30%, WEC was 7800 
and the ESR was elevated to 28. The urine 
showed ++ protein and 20-25 RBC/hpf. Reversal 
of the albumin:globulin ratio (3.5/3.8) was 
noted. Five of five initial cultures (10 
bottles) grew alpha-hemolytic streptococcus 
equivocally sensitive to kanamycin and strepto¬ 
mycin and sensitive to all other antibiotics 
tested. Therapy was begun with Penicillin~G 
in a daily dose of 10 million units and this was 
continued for 26 days with the patient intermittently 
febrile during therapy. Pen-V-K (4g/d) was given 
for an additional 20 days but the patient con¬ 
tinued to have fever and new petechiae were noted. 
Multiple blood cultures showed no growth. The 
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patient underwent surgery where findings 
included large vegetations and a small mycotic 
aneurysm near the aortic valve ring. AV re™ 
placement and resection of the aneurysm were car¬ 
ried out. Cultures of blood and operative 
specimens were sterile. The patient became a- 
febrile post-operatively and has been followed 
for eight years in good health. 
CASE 58-PERSISTENT FEVER: A 31 year old 
white female was admitted to the hospital 
because of chest pain and CHF. She was preg¬ 
nant at 33 weeks gestation. There was no 
history of cardiac disease, although an apical 
systolic murmur had been noted intermittently 
during pregnancy and on one occasion previously. 
She was afebrile on admission. The hematocrit 
was 25, the WBC 10,250 and ESR 30. The urine 
showed 0-4 RBC/hpf in several specimens. The 
RF was negative (Titer 1:20) and there was rever¬ 
sal of the albumin:globulin ratio (1.9:3.1). Two 
of eight sets of blood cultures grew alpha 
hemolytic streptococcus. The MIC of penicillin 
for this organism was 0.045 ug/ml. The patient 
was treated for two weeks with penicillin (20 
million units per day) and streptomycin (1.0 
gram per day) and for one week more with penicillin 
alone. Fever persisted during treatment despite 
the achievement of adequate serum bactericidal 
levels (1:512) and sterile blood cultures. It was 
decided to undertake operation and a cage ball 
prosthesis was placed. Significant tissue destruc¬ 
tion in the region of the AV was noted but, again, 
operative specimens yielded no growth on culture. 
The patient became afebrile and was doing well 
until, some four years later, she died suddenly 
(presumed secondary to a myocardial infarction). 
CASE 50-PERSISTENT FEVER: This patient was 
a 20 year old white female who presented to the 
hospital after six weeks of illness with fever, 
chills, sweats, weight loss, and weakness and 
malaise. Her past history was remarkable for an 
aortic valvuloplasty with a suture remaining in 
the reconstructed valve. In addition to a 
systolic murmur, there was a question of spleno¬ 
megaly on physical exam. The hematocrit was 27, 
the WBC 2700 and the ESR was 40 but corrected to 
12. RF was present only in a titer of 1:20; the 
albumin:globulin ratio was reversed 3.1:3.7. 
Cultures grew microaerophilic alpha-hemolytic 
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streptococcus inhibited by 0.18 ug/ml of 
penicillin. Therapy was initiated w7ith 
penicillin alone (12 million units/day) 
but after six days there was no clinical 
improvement and streptomycin was added 
(1.0 gram/day). Two weeks into therapy, 
still febrile, she was changed to Keflin 
(8.0g/d). Streptomycin was continued. Many 
cultures were performed and all were sterile. 
Serum cidal levels were consistently adequate 
(up to 1:1028). After a total of 34 days of 
therapy AV replacement was performed and the 
patient became afebrile. At operation large 
vegetations and significant tissue destruction 
were observed. Cultures were sterile. She 
has been in good health for nine years and is 
still followed regularly. 
There were five deaths among the 68 patients in this 
series, four in Group I and one in Group II. This difference 
was not significant (p >0.50). One patient in Group I 
died shortly after sustaining a relapse and will be discussed 
later. Case summaries for the other four patients who died 
appear below. 
CASE 37-DEATH: Only a discharge summary 
and autopsy report is available on this 67 
year old white male treated at the WHVAH. He 
had a history of ethanol abuse with slight 
hepatic impairment. The duration of illness 
is not known, but he was obtunded and febrile 
on presentation. Physical examination revealed 
a cachectic man with a grade II/VI systolic 
murmur and the stigmata of liver disease. The 
hematocrit was 30 and the WBC 13,050. The urine 
showed 4- protein. Blood cultures grew S. viridans 
which was very sensitive by tube dilutions. He 
was treated with 10 million units per day of IV 
penicillin initially and then continued on 1.2 
million units of procaine penicillin every 12 
hours. He improved neurologically but developed 
aortic insufficiency and CHF. He died suddenly 
just after completion of a four week course of 
therapy. Post mortem examination revealed vege¬ 
tations about the AV with non-viable gram¬ 
positive cocci apparant on smear. There was 
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"acute suppurative pancarditis" in addition 
to a sterile coronary artery embolus, an 
acute splenic infarct and hepatic cirrhosis. 
CASE 49-DEATH: A 76 year old white female 
with RHD and mitral regurgitation was admitted 
to the hospital because of fever, weakness and 
malaise, and weight loss of six weeks duration. 
The temperature was 102°F. Physical examination 
was remarkable for a grade III/VI holosystolic 
murmur and splenomegaly. The hematocrit was 
29, W3C 4700, and ESR 58. There was ++ protein 
and several RBC/hpf on examination of the urine. 
The albumin:globulin ratio was reversed (2.9:4.0). 
Four of four initial blood cultures grew alpha- 
hemolytic streptococcus with an MIC of Q.19u/ml 
of penicillin. Treatment was begun with penicillin-G 
(24 million units/day) and streptomycin (2.0 grams/ 
day), the latter being discontinued after three 
days. A rash developed and the temperature, which 
had normalized, rose on the sixth hospital day. 
Penicillin was stopped, and Keflin (6g/d) was 
begun. The patient defervesced and appeared to 
be doing well but was found comatose on the 
thirteenth day of hospitalization and died that 
same day. Autopsy demonstrated a cerebral 
hemorrhage although no definite mycotic aneurysm 
was discerned. All cultures were negative. 
CASE 48-DEATH: A 67 year old white male who 
had undergone AV replacement seven years earlier, 
was admitted to the WHVAH with a two week his¬ 
tory of fever, chills, weakness and malaise. 
His temperature was 101°F, a grade II/VI systolic 
ejection murmur was heard and a question of 
splenomegaly was raised. The hematocrit was 39.5, 
the WBC 10,900 and the ESR was 34. RF was present 
in a titer of 1:80 and subsequently rose to 
1:160. The urine was benign and the ratio of 
albumin:globulin was normal. Three of three sets 
of blood cultures grew S. bovis. Because 
there was a history of penicillin allergy, the 
patient was treated with vancomycin (500mg IV every 
6 hours) for three days and Keflin (8.0g/d) for 
another four days. During this week, the patient 
also received three days of an aminoglycoside. 
Tube dilution sensitivities for this organism were 
carried out with vancomycin revealing both MIC 
and MBC to be 0.39ug/ml. Serum cidal levels on 
Keflin were 1:8 and on vancomycin, 1:16. The 
patient appeared to be doing well but was found 
dead on the eighth hospital day. 
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Autopsy failed to reveal a specific cause 
of death but this was presumed to be CHF. 
Findings included large vegetations and 
acute fibrinous pericarditis. There was 
generalized atherosclerosis and four chamber 
cardiac enlargement. Focal myocardial 
fibrosis, both old and recent, was noted. 
All cultures, once again, were sterile. 
CASE 69-DEATH: A 49 year old black male 
with RHD and a history of AV replacement 
and mitral commisurotomy, experiences spiking 
temperatures to 104°F and was admitted to 
another hospital. Six blood cultures grew 
S. viridans inhibited by penicillin at 0.012 
u/ml. There was a loud diastolic rumble and 
a loud holosystolic murmur as well. Penicillin 
was administered beginning on the third hospi¬ 
tal day in a dose of 20-24 million units per 
day achieving serum inhibitory titers of 1:64 
but cidal levels of only 1:2. CHF and pre- 
renal azotemia complicated the course. On the 
eleventh hospital day, penicillin dosage was 
increased, probenecid was added and strepto¬ 
mycin-1 . Og/d-was begun. This therapy was 
maintained for the next eight days and serum 
cidal levels rose to 1:128. Cardiac failure 
worsened. Chest pain and a pleural rub required 
heparin administration. Hypotension developed 
and the patient became intermittently dependent 
on pressors. The patient was transferred to 
YNHH three weeks after his original admission. 
Emergency MV and TV replacement was undertaken 
but the patient became increasingly hypotensive 
and acidotic post-operatively. He died on the 
first post-operative day. 
Post-mortem examination was remarkable for 
massive hypertrophy and dilatation of the heart 
(weight:980g), a possible recent anteroseptal 
myocardial infarction, a recent, large pulmonary 
infarction and prominent pulmonary arteriosclerosis. 
No growth was produced in multiple cultures of 
blood and tissue. 
The final and most important category to consider 
in the evaluation of the antimicrobial treatment of IE is 
recurrent disease. There were two bacteriologically proven 
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relapses in this patient population (rate: 2/68=3%). 
Both patients were readmitted within one month of their 
original discharge. (The only other patient who received 
two courses of therapy in our group was judged to have had 
a reinfection based on the fact that a disease-free inter¬ 
val of more than one year had passed from the time he 
originally completed therapy until new symptoms were noted.) 
Both patients who relapsed were treated with penicillin 
only but the rate of relapse for Group I (2/49 or 40%) was 
not significantly greater than for Group II (0/19, p > 0.50). 
CASE 38-RELAPSE LEADING TO DEATH: A 63 
year old white male was admitted to another 
hospital because of anemia, fever, cardio- 
megaly and a heart murmur. He had been in 
excellent health until four months earlier 
when he developed symptoms of CAD with a 
question of inferior wall myocardial 
infarction and very mild CHF. He was 
treated with nitrates. For some years he 
had been aware of the presence of a murmur. 
On admission there was a low grade fever and a 
grade III/VI holosystolic murmur that radiated 
from the apex to the left axilla. Six blood 
cultures were positive for S. viridans. The 
patient was treated with 10 million units of 
penicillin-G daily, for 21 days. He improved 
and was discharged. Two weeks after discharge 
he re-presented to the same hospital with 
symptoms of CHF. He was transferred to YNHH 
for evaluation. On admission, a grade III/VI 
murmur of MR was again noted. There were 
scattered petechiae on the right leg. The 
hematocrit was 34.1, WBC 5000 and ESR 53. 
Three of three sets of blood cultures were 
positive for S. viridans. Treatment with 
penicillin-G (20 million units/day) was begun 
on the third hospital day. Streptomycin was 
added to the regimen on day four. Two days 
later the patient sustained a cardiorespiratory 
arrest and could not be resuscitated. Permission 
for autopsy was denied. 
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CASE 39-RELAPSE: A 63 year old white 
male was admitted to the hospital complain¬ 
ing of lethargy, fatigue and weight loss. 
There was no known cardiac history. Physi¬ 
cal examination revealed a low grade fever, 
palatine petechiae, splinter hemorrhages 
and the murmurs of aortic stenosis and 
insufficiency. The patient was anemic with 
an hematocrit of 31.1; the WBC was 8100 and 
the ESR was 60. The titer of RF was 1:80; 
albumin was 2.9, globulin was 3.2. Nine 
blood cultures grew alpha-hemolvtic strep¬ 
tococcus with an MIC of 0.098 ug/ml of 
penicillin. Penicillin was given at a dose 
of 12 million units daily by intermittent 
intravenous infusion for the first seven 
days and, subsequently, procaine penicillin 
2.4 million units per day was given for an 
additional 14 days. Serum cidal levels were 
determined on the day that the route of 
administration of antibiotic was changed and 
showed adequate bactericidal activity (titer 
1:16). The patient improved and was dis¬ 
charged only to be readmitted three weeks 
later with a recurrence of fever, weakness 
and anorexia. The ESR was still 60 and the 
RF was positive at 1:320. Again, seven of 
seven blood cultures grew alpha-hemolytic 
streptococcus with an MIC of 0.078 ug/ml of 
penicillin. Treatment was undertaken with 
intravenous penicillin. Twenty million units 
were administered each day for the first 
three days and then 6,000,000 units were 
given daily for an additional 38 days. The 
patient was discharged in good condition and 
did very well over the next year. He remained 
completely asymptomatic. 
Unfortunately he suffered a third bout of 
streptococcal endocarditis some 13 months 
after completing the above therapeutic course. 
This third infection, alluded to earlier in 
this section, was judged a reinfection and 
was treated successfully with penicillin. He 
has since been followed for five years during 
which time he has been in good health. 
In conclusion, it should be noted that these data 
were extensively analyzed to ascertain whether any statisti¬ 
cally significant difference in outcome between Group I and 
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Group II could be demonstrated by grouping various combina¬ 
tions of complications together. Accordingly Groups I and 
II were compared with respect to the percentage of patients 
in each who developed: 
a) CHF or emboli 
b) CHF, emboli, or death 
c) CHF, emboli, relapse, persistent fever or death 
d) CHF, relapse, fever or death 
e) Relapse, fever, or death 
f) Relapse or fever 
g) Relapse or death 
h) Relapse, death or emboli. 
No significant difference between the two groups was observed 
(p:0.20-0 » 50). 
Moreover, the data was studied by anatomical site 
of endocarditis with separate analysis of AV patients, MV 
patients, patients with prostheses, patients with non- 
valvular congenital heart lesions, patients with either 
AV or MV endocarditis, and, finally, all non-prosthetic 
patients. In carrying out these analyses Groups I and II 
were compared with respect to the percentage of patients 
in each who developed: 
a) any one of the five major complications 
previously defined 
b) each of the five major complications, and 
c) any of the combinations (a-h) listed above. 
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In the literally scores of comparisons thus performed, no 
difference was significant and all "p" values were greater 
than 0.20. 

DISCUSSION 
In the present study 68 courses of therapy were 
administered. It would appear that sterilization of 
endocardial vegetations was achieved in 66 of 68 cases, 
regardless of the treatment regimen employed. Operative 
or post-mortem specimens were cultured and were sterile 
in all 3 instances of persistent fever and in all patients 
who died without relapse. Follow up for at least six 
months was available for all other patients. 
Two of 68 patients, however, did sustain bacteriologic 
relapse; both of these episodes of recurrent disease occurred 
in patients treated with a single drug regimen (Group I). 
Comparison of Groups I and II reveals no statistical 
differences in site of involvement of endocardial infection, 
duration of therapy, underlying disorders or rates of 
complications. However, the prevalence of patients who 
were greater than 60 years of age, as well as the prevalence 
of patients in whom the duration of illness was greater than, 
or equal to, three months, were significantly greater in 
Group I. Both of these factors have been demonstrated here 
and elsewhere (32,42), to adversely affect outcome, and 
specifically, to predispose to recurrent endocarditis. 
Thus, a significantly greater proportion of patients in 
Group I vere at "risk" for relapse than in Group II. 
72 
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Indeed both patients who relapsed had both risk factors. 
Moreover, relapse may have occurred in the two 
patients because of inadequate therapy. It should be 
noted that controversy exists over both dosage and duration 
of therapy for the treatment of this disease (45), and, 
therefore standards for treatment have been derived 
empirically. Although some investigators do not feel 
that the fibrin layer prevents diffusion of antibiotics 
into the endocardial vegetation, the central necrotic 
portion of the lesion is where bacteria reside and it 
appears that penetration into this space, at least of 
leukocyles is retarded until the outer fibrin layer has 
been vascularized (29). Clearly, duration of therapy must 
be critical under these conditions. 
In addition, it would appear that plasma peak levels 
of penicillin are the major factor in determining the degree 
of antibiotic penetration and activity (12,43). Therefore, 
intravenous therapy, with a larger instantaneous pulse of 
antibiotic, would offer significant advantage over intra¬ 
muscular procaine penicillin in this disease. 
In the present series both patients who relapsed 
were treated for only three weeks and while one of these 
patients received high doses of intravenous penicillin 
(10 MU/d), the other received relatively low doses by 
intramuscular injection (2-4 MU procaine penicillin). It 
may be argued therefore that in one patient therapy was 
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inadequate because of duration and in the other because 
of both dose and duration. 
In light of the evidence that combination of an 
aminoglycoside with penicillin results in more efficient 
eradication of streptococci, in vitro and in vivo (as 
discussed above), it is possible that the addition of 
streptomycin to the treatment regimen of the two patients 
who relapsed after three weeks of therapy, may have 
prevented these treatment failures. The findings of Phair 
and Tan (32) however, cited, above would indicate that 
combination therapy surely does not guarantee bacteriologic 
cure, especially with longstanding endocarditis, even when 
the total duration of such therapy is four week or more. 
It would appear, from the data presented here, and 
the findings of Phair and Tan, that when patients with 
penicillin-sensitive streptococcal IE who do not have 
longstanding illness receive appropriate dosage and dura¬ 
tion of penicillin therapy, they fare as well as cohorts 
receiving combination therapy. 
The importance of this last observation is obvious. 
Protracted aminoglycoside therapy is not without hazard, 
especially in the presence of pre-existent renal compromise. 
The opportunity to spare patients exposure to aminoglycoside 
toxicity is thus suggested by the results of the present 
study. 
It should be noted, however, that the issue is 
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less clear for patients at high risk for recurrent disease, 
especially those in whom the duration of illness is greater 
than three months. In the present study, two of eleven 
patients (18%) with a three month history relapsed after 
single agent therapy as compared with zero of two patients 
treated with combination therapy. Phair and Tan observed 
that one of three single agent recipients (33%) relapsed 
as compared with two of seven patients (29%) treated with 
two drugs. Pooling these results yields relapse rates of 
21% and 22% for single and combination therapy, respectively. 
This difference is obviously insignificant and would 
suggest that, in fact, the addition of an aminoglycoside 
makes little difference in treating these patients, pro- 
vided that total duration of therapy is sufficient. It 
should be kept in mind, however, that these comparisons 
are based on very small samples and thus need to be inter¬ 
preted with caution. 
In dealing with a treatment failure rate of less 
than 5% regardless of therapy, an extremely large number 
of patients would be required to definitively settle this 
question. Although a prospective, multi-center trial 
would be appropriate, a careful analysis of retrospective 
data from this study and a review of the literature, strongly 
suggest that the treatment of choice for patients with non- 
enterococcal penicillin-sensitive streptococcal IE, who do 
not have longstanding illness (i.e.,^3 months), is 
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intravenous penicillin in a dosage that is at least 6 
million units per day and that is sufficient to ensure 
serum bactericidal levels of at least 1:8 (36), for a 
duration of not less than four weeks. Although there is 
good evidence that this same regimen may be comparable 
to combined penicillin-streptomycin regimens of equal 
duration in the treatment of longstanding illness, more 
careful judgment of the relative risks of aminoglycoside 
toxicity and relapse from IE is warranted in these patients. 
Finally, it should be noted that patients with 
prosthetic valves may have a different clinical course 
with a much shorter symptomatic period prior to diagnosis. 
Their prognosis, despite a short duration of illness, is 
extremely poor and this factor (i.e., duration of illness) 
may not be relevant in this subgroup of IE patients. 
Therefore, all patients with prostheses should be regarded 
as high risk patients and the addition of an aminoglycoside 
to their treatment regimen considered. 
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